Cardiff Oncology, Inc. [CRDF]

Source: 

Company Overview

We are a clinical-stage, biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer (mCRC), pancreatic cancer, metastatic castrate-resistant prostate cancer (mCRPC) and leukemias. By integrating biomarkers into our clinical development programs, we will be able to identify patients who are most likely to respond to treatment across a number of cancer types and associated indications